These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 30160591)

  • 1. Blood graft composition and post-transplant recovery in myeloma patients mobilized with plerixafor: a prospective multicenter study.
    Valtola J; Silvennoinen R; Ropponen A; Siitonen T; Säily M; Sankelo M; Putkonen M; Partanen A; Pyörälä M; Savolainen ER; Mäntymaa P; Pelkonen J; Jantunen E; Varmavuo V
    Leuk Lymphoma; 2019 Feb; 60(2):453-461. PubMed ID: 30160591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low-dose cyclophosphamide: a randomized comparison.
    Valtola J; Silvennoinen R; Ropponen A; Siitonen T; Säily M; Sankelo M; Terävä V; Putkonen M; Kuittinen T; Pelkonen J; Mäntymaa P; Remes K; Varmavuo V; Jantunen E
    Transfusion; 2016 Jun; 56(6):1394-401. PubMed ID: 27041692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood graft composition after plerixafor injection in patients with NHL.
    Varmavuo V; Mäntymaa P; Nousiainen T; Valonen P; Kuittinen T; Jantunen E
    Eur J Haematol; 2012 Aug; 89(2):128-35. PubMed ID: 22536949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma.
    Tolomelli G; Mancuso K; Tacchetti P; Patriarca F; Galli M; Pantani L; Zannetti B; Motta MR; Rizzi S; Dan E; Sinigaglia B; Giudice V; Olmo A; Arpinati M; Chirumbolo G; Fanin R; Lewis RE; Paris L; Bonifazi F; Cavo M; Curti A; Lemoli RM
    Bone Marrow Transplant; 2020 May; 55(5):946-954. PubMed ID: 31768009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood graft cellular composition and posttransplant recovery in non-Hodgkin's lymphoma patients mobilized with or without plerixafor: a prospective comparison.
    Valtola J; Varmavuo V; Ropponen A; Nihtinen A; Partanen A; Vasala K; Lehtonen P; Penttilä K; Pyörälä M; Kuittinen T; Silvennoinen R; Nousiainen T; Pelkonen J; Mäntymaa P; Jantunen E
    Transfusion; 2015 Oct; 55(10):2358-68. PubMed ID: 26018461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
    Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
    Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes of multiple myeloma patients who undergo autologous hematopoietic stem cell transplant with G-CSF or G-CSF and plerixafor mobilized grafts.
    Shah H; Kim S; Singh P; Alavi A; Ratanatharathorn V; Ayash L; Uberti J; Deol A
    Am J Hematol; 2020 Feb; 95(2):198-204. PubMed ID: 31691333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autograft cellular composition and outcome in myeloma patients: Results of the prospective multicenter GOA study.
    Turunen A; Silvennoinen R; Partanen A; Valtola J; Siitonen T; Putkonen M; Sankelo M; Pyörälä M; Kuittinen T; Penttilä K; Sikiö A; Savolainen ER; Mäntymaa P; Pelkonen J; Varmavuo V; Jantunen E
    Transfusion; 2021 Jun; 61(6):1830-1844. PubMed ID: 33955591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of lenalidomide-based induction therapy on the mobilization of CD34
    Partanen A; Valtola J; Silvennoinen R; Ropponen A; Siitonen T; Putkonen M; Sankelo M; Pelkonen J; Mäntymaa P; Varmavuo V; Jantunen E
    Transfusion; 2017 Oct; 57(10):2366-2372. PubMed ID: 28681435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of CD34
    Anu P; Antti T; Raija S; Marja P; Jaakko V; Timo S; Mervi P; Marja S; Anu S; Karri P; Taru K; Jukka P; Pentti M; Esa J; Ville V
    Transfusion; 2021 Nov; 61(11):3202-3212. PubMed ID: 34498764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The composition of leukapheresis products impacts on the hematopoietic recovery after autologous transplantation independently of the mobilization regimen.
    Menéndez P; Caballero MD; Prosper F; Del Cañizo MC; Pérez-Simón JA; Mateos MV; Nieto MJ; Corral M; Romero M; García-Conde J; Montalbán MA; San Miguel JF; Orfao A
    Transfusion; 2002 Sep; 42(9):1159-72. PubMed ID: 12430673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens.
    Jantunen E; Fruehauf S
    Bone Marrow Transplant; 2011 May; 46(5):627-35. PubMed ID: 21217789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy assessment of plerixafor in patients with multiple myeloma proven or predicted to be poor mobilizers, including assessment of tumor cell mobilization.
    Tricot G; Cottler-Fox MH; Calandra G
    Bone Marrow Transplant; 2010 Jan; 45(1):63-8. PubMed ID: 19543330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.
    Baertsch MA; Schlenzka J; Lisenko K; Krzykalla J; Becker N; Weisel K; Noppeney R; Martin H; Lindemann HW; Haenel M; Nogai A; Scheid C; Salwender H; Fenk R; Graeven U; Reimer P; Schmidt-Hieber M; Goerner M; Schmidt-Wolf IGH; Klein S; Ho AD; Goldschmidt H; Wuchter P
    Eur J Haematol; 2017 Jul; 99(1):42-50. PubMed ID: 28370401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal chemo-mobilization for the collection of peripheral blood stem cells in patients with multiple myeloma.
    Song GY; Jung SH; Ahn SY; Jung SY; Yang DH; Ahn JS; Kim HJ; Lee JJ
    BMC Cancer; 2019 Jan; 19(1):59. PubMed ID: 30642286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma.
    Lin TL; Wang PN; Kuo MC; Hung YH; Chang H; Tang TC
    J Clin Apher; 2016 Oct; 31(5):423-8. PubMed ID: 26340986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the number of cryopreserved CD34
    Partanen A; Turunen A; Silvennoinen R; Valtola J; Pyörälä M; Siitonen T; Sikiö A; Putkonen M; Sankelo M; Penttilä K; Kuittinen T; Mäntymaa P; Pelkonen J; Jantunen E; Varmavuo V
    J Clin Apher; 2023 Feb; 38(1):33-44. PubMed ID: 36239392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Joint Modeling of Immune Reconstitution Post Haploidentical Stem Cell Transplantation in Pediatric Patients With Acute Leukemia Comparing CD34
    Salzmann-Manrique E; Bremm M; Huenecke S; Stech M; Orth A; Eyrich M; Schulz A; Esser R; Klingebiel T; Bader P; Herrmann E; Koehl U
    Front Immunol; 2018; 9():1841. PubMed ID: 30154788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective randomized trial of two popular mononuclear cell collection sets for autologous peripheral blood stem cell collection in multiple myeloma.
    Cooling L; Hoffmann S; Herrst M; Muck C; Armelagos H; Davenport R
    Transfusion; 2010 Jan; 50(1):100-19. PubMed ID: 19719472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.